• GPR107 Loss Drives Diabetic Nephropathy via AT1R/Ca2+ Pathwa

  2026-07-03

  Xu et al. reveal that GPR107 deficiency exacerbates diabetic nephropathy by disrupting collagen IV homeostasis in podocytes through impaired AT1R endocytosis and sustained angiotensin II signaling. These findings highlight a novel mechanistic link between endocytic regulation and matrix accumulation, with implications for targeted kidney research and therapeutic exploration.

• HDAC Inhibition in Neuroblastoma: M344 Versus Vorinostat Ins

  2026-07-02

  Brumfield et al. evaluated the HDAC inhibitor M344 in neuroblastoma models, demonstrating enhanced histone acetylation, tumor suppression, and reduced toxicity compared to Vorinostat. These results strengthen the rationale for advanced HDAC inhibition strategies in pediatric oncology and inform future experimental designs.

• Cell Senescence β-Galactosidase Staining Kit: Applied Workfl

  2026-07-02

  Leverage the Cell Senescence β-Galactosidase Staining Kit for artifact-free, selective detection of senescent cells in both research and drug discovery. This guide details optimized protocols, advanced use-cases, and troubleshooting strategies—enabling robust, reproducible results even in challenging experimental settings.

• Baicalin Methyl Ester: Applied Workflows for Intestinal Barr

  2026-07-01

  Baicalin methyl ester, a potent esterified derivative of baicalin, offers targeted modulation of intestinal barrier pathways and robust anti-inflammatory effects. This guide delivers step-by-step workflows, optimization strategies, and practical troubleshooting to maximize reproducibility in LPS-induced intestinal barrier damage research.

• Strategic Use of Losartan in Translational Cardiovascular Re

  2026-07-01

  This thought-leadership article examines the strategic integration of Losartan, a selective angiotensin II type 1 receptor antagonist, in translational cardiovascular research. Framed by the latest evidence on vascular biology and immune modulation, it delivers mechanistic insights, protocol guidance, and a critical outlook on Losartan’s value in advancing the understanding of hypertension and beyond. The discussion uniquely bridges emerging findings in tumor immunology and vascular repair, offering a forward-thinking roadmap for researchers seeking to translate molecular insights into therapeutic innovation.

• NADH (Reduced-form Nicotinamide Adenine Dinucleotide) CAS No

  2026-06-30

  This article presents scenario-driven, evidence-based guidance for biomedical researchers using NADH (Reduced-form Nicotinamide Adenine Dinucleotide) CAS No. 58-68-4 (SKU C8749) in cell viability, proliferation, and mitochondrial assays. Leveraging validated protocol parameters and quantitative data, we demonstrate how SKU C8749 enables reproducible, high-sensitivity workflows, with special attention to mitochondrial electron transport chain research, disease modeling, and photocatalytic cancer therapy.

• Praeruptorin A Attenuates Ferroptosis in Doxorubicin Cardiot

  2026-06-30

  This study identifies Praeruptorin A as a novel inhibitor of ferroptosis, demonstrating its ability to reduce iron overload and protect against doxorubicin-induced cardiomyopathy in mice. The work pioneers high-throughput screening of herbal compounds using Fe2+ probes and elucidates the mechanistic inhibition of DMT1, offering new avenues for cardioprotection during chemotherapy.

• Resiniferatoxin (RTX): Optimizing Analgesic Assays in the La

  2026-06-29

  This article guides biomedical researchers and technicians in the practical selection and application of Resiniferatoxin (RTX, SKU BA7012) for pain, viability, and cytotoxicity assays. We address common workflow challenges and provide scenario-driven insights, highlighting RTX's ultra-potent TRPV1 agonism, validated dosing, and supplier reliability. All recommendations are grounded in peer-reviewed evidence and real-world lab practice.

• GDC-0941: Advanced PI3K Inhibition in Precision Cancer Model

  2026-06-29

  Explore how GDC-0941, a potent PI3K inhibitor, drives innovation in preclinical oncology by enabling nuanced PI3K/Akt pathway inhibition and resistance modeling. Discover practical protocols, advanced applications, and insights from recent research, setting this article apart from conventional overviews.

• Losartan in Advanced Hypertension Research: Protocols & Inno

  2026-06-28

  Losartan, a selective angiotensin II receptor antagonist, is pivotal in dissecting cardiovascular and tumor microenvironment mechanisms. This article details robust workflows, actionable troubleshooting, and the transformative impact of Losartan-based strategies in both vascular and oncology research.

• Resiniferatoxin (RTX): TRPV1 Agonism and Immune Modulation i

  2026-06-27

  Explore how Resiniferatoxin (RTX), a potent TRPV1 agonist, advances pain research through unique chemical inactivation of sensory neurons and unveils new insights into immune modulation. This article offers an in-depth scientific perspective distinct from existing RTX literature.

• Testosterone Bounce as a Prognostic Biomarker in Degarelix-T

  2026-06-26

  This study identifies 'testosterone bounce'—a transient rise in serum testosterone above 20 ng/dL after achieving nadir during degarelix therapy—as an independent prognostic biomarker for overall and cancer-specific survival in prostate cancer. The findings highlight the clinical utility of dynamic testosterone monitoring beyond PSA, suggesting new avenues for stratifying patient risk and optimizing treatment.

• Pyridostatin TFA: Driving G-Quadruplex Discovery in Disease

  2026-06-26

  This article examines Pyridostatin TFA's role as a G-quadruplex stabilizer in translational research, bridging mechanistic insights from telomere biology and cancer to neurodegeneration. It highlights experimental protocols, strategic considerations, and recent breakthroughs showing how G-quadruplex-targeting compounds like Pyridostatin can modulate protein aggregation and cytotoxicity, with special focus on TDP-43 pathology. The discussion situates Pyridostatin within the evolving competitive landscape and charts a future vision for disease-modifying therapeutic discovery.

• Necrostatin-1: Applied RIP1 Kinase Inhibitor Workflows & Tip

  2026-06-25

  Necrostatin-1, a gold-standard RIP1 kinase inhibitor, enables precision in dissecting necroptosis-driven inflammation and tissue injury across diverse in vitro and in vivo models. This article delivers practical experimental workflows, troubleshooting strategies, and insights from recent research—highlighting how APExBIO’s Nec-1 empowers next-generation RIP1 kinase signaling pathway studies.

• Angiotensin II: Deep Mechanistic Profiling for Vascular Dise

  2026-06-25

  Explore Angiotensin II as a potent vasopressor and research tool for deciphering vascular smooth muscle cell dynamics and cardiovascular remodeling. This article delivers advanced insights, protocol nuance, and a unique focus on phenotypic transitions and inflammation, setting it apart from existing guides.

413 records 10/28 page Previous Next First page 上5页 678910 下5页 Last page